Heike Richly

3.3k citations

56 papers · 2.4k indexed · 1 hit paper · h-index 20

Impact in

Hepatology top 2%
- Hepatocellular Carcinoma Treatment and Prognosis
Oncology top 2%
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology

Papers in

Oncology 32
- Cancer Treatment and Pharmacology 20
- Colorectal Cancer Treatments and Studies 8
- HER2/EGFR in Cancer Research 6
Ophthalmology 8
- Ocular Oncology and Treatments 8

Co-authors: Dirk Strumberg M. E. Scheulen Brian Schwartz Ralf A. Hilger Ahmad Awada E. Brendel S. Seeber R. Voigtmann
Journals: Journal of Clinical Oncology (17 papers)Annals of Oncology (6 papers)European Journal of Cancer (5 papers)Cancer Chemotherapy and Pharmacology (2 papers)Cancer Research (2 papers)
Partner nations: Germany United States Switzerland

In The Last Decade

Heike Richly

53 papers receiving 2.3k citations

Hit Papers

align trajectories log scale

Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors 2004 · 694 citations

Peers

Countries citing papers authored by Heike Richly

Since Specialization

Citations

This map shows the geographic impact of Heike Richly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heike Richly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heike Richly more than expected).

Fields of papers citing papers by Heike Richly

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heike Richly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heike Richly. The network helps show where Heike Richly may publish in the future.

Co-authors

The 25 scholars most cited alongside Heike Richly, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Heike Richly Line = papers co-authored together Heike Richly links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Prognostic value of clinical and radiomic parameters in patients with liver metastases from uveal melanoma Pigment Cell & Melanoma Research ·M. J. Lever, Simon Bogner, 千慧子倪, Fabian Mairinger, Hideo A. Baba, Heike Richly, Tanja Gromke, Martin Schüler, Nikolaos E. Bechrakis, Halime Kalkavan	2024	0
2	Radiation Dose Aspects of Hepatic Artery Infusion Chemotherapy in Uveal Melanoma Patients with Liver Metastases CardioVascular and Interventional Radiology ·Paulo Rogério Moritz Postigo, Marcel Opitz, Johannes Ludwig, Johannes Haubold, Heike Richly, Jens T. Siveke, Jens Theysohn, Michael Forsting, Mabizela, Benedikt M. Schaarschmidt	2022	0
3	Predictive impact of the inflammation-based indices in uveal melanoma liver metastases treated with transarterial hepatic chemoperfusion Radiology and Oncology ·Johannes Ludwig, Johannes Haubold, Sebastian Bauer, Heike Richly, Jens T. Siveke, Julia Wimmer, Lale Umutlu, Benedikt M. Schaarschmidt, Jens Theysohn	2021	9
4	Improved survival in metastatic breast cancer: results from a 20-year study involving 1033 women treated at a single comprehensive cancer center Journal of Cancer Research and Clinical Oncology ·Anja Welt, Simon Bogner, Marina Arendt, 金會千, Динара Балгабековна Имангазинова, Christian Pohlkamp, Eko Yulinggar Permana, Laura McCluskey, Ferras Alashkar, أ جواهر فهد فريج الدوسري مشترك, Marcel Wiesweg, Heike Richly, J. Hense, M. E. Scheulen, Martin Schüler, S. Seeber, Mitra Tewes	2020	15
5	A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors Cancer Chemotherapy and Pharmacology ·K. Mross, Heike Richly, Annette Frost, Qiqi Liao, Yulian Zhang, Ralph Graeser, Adrian Bojenoiu, James Hilbert, J. WALTER ELLIOTT, Yuchen Zhang, M. E. Scheulen	2016	14
6	A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer European Journal of Cancer ·Lothar Bergmann, Luise Maute, Gerhard Heil, Jörn Rüssel, Eckhart Weidmann, Dieter Köberle, Stefan Fuxius, K. Weigang-Köhler, Walter E. Aulitzky, Bernhard Wörmann, G. Hartung, Berta Moritz, Lutz Edler, Iris Burkholder, M. E. Scheulen, Heike Richly	2014	51
7	Phase I clinical study of the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumours European Journal of Cancer ·Martin R. Weihrauch, Heike Richly, Michael S. von Bergwelt‐Baildon, H. Becker, Manuel Schmidt, Ulrich Hacker, Alexander Shimabukuro‐Vornhagen, Udo Holtick, Yulian Zhang, Matthias Schroff, Burghardt Wittig, M. E. Scheulen	2014	54
8	First-in-Human Phase I Study of PRS-050 (Angiocal), an Anticalin Targeting and Antagonizing VEGF-A, in Patients with Advanced Solid Tumors PLoS ONE ·K. Mross, Heike Richly, Richard Fischer, Qiqi Liao, Martin Büchert, 五條しおり, Hendrik Gille, Laurent Audoly, M. E. Scheulen	2013	41
9	A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer Breast Cancer Research and Treatment ·Erica L. Mayer, M. E. Scheulen, Joshua A. Beckman, Heike Richly, Mostafa Adineh, Monette Cotreau, Andrew Strahs, Shefali Agarwal, Linda S. Steelman, Eric P. Winer, Maura N. Dickler	2013	21
10	A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors Cancer Chemotherapy and Pharmacology ·Ruth Plummer, Ayman Madi, B Roberts, Heike Richly, Yulian Zhang, Stephen D. Rubin, Howard Ball, Steve Weller, Jeffrey Botbyl, D. Gibson, M. E. Scheulen	2012	25
11	Pharmacokinetics of sorafenib in patients with renal impairment undergoing hemodialysis International Journal of Clinical Pharmacology and Therapeutics ·Ralf A. Hilger, Heike Richly, M. Grubert, Мелехова Кристина Павловна, W Jullien, Wilfried Eberhardt, J. Hense, Martin Schüler, M. E. Scheulen	2009	31
12	Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: Results from a phase I extension trial European Journal of Cancer ·Heike Richly, Beate Schultheis, Irenäus A. Adamietz, P. Kupsch, M. Grubert, Ralf A. Hilger, Matthias Ludwig, E. Brendel, O. Christensen, Dirk Strumberg	2008	68
13	Results of a Phase I Trial of Sorafenib (BAY 43-9006) in Combination with Oxaliplatin in Patients with Refractory Solid Tumors, Including Colorectal Cancer Clinical Colorectal Cancer ·P. Kupsch, Bernhard F. Henning, Μαρία Ιωάννης Μαρίνη, Heike Richly, Ekrem Benzer, Ralf A. Hilger, M. E. Scheulen, Olaf Christensen, E. Brendel, Brian Schwartz, 张矣韵, R. Voigtmann, S. Seeber, Dirk Strumberg	2005	99
14	Pharmacokinetics (PK) of a liposomal encapsulated fraction containing doxorubicin and of doxorubicin released from the liposomal capsule after intravenous infusion of Caelyx?/Doxil International Journal of Clinical Pharmacology and Therapeutics ·Ralf A. Hilger, Heike Richly, M. Grubert, C. Oberhoff, Dirk Strumberg, M. E. Scheulen, S. Seeber	2005	18
15	Phase I clinical and pharmacokinetic study of BBR 3576, a novel aza-anthrapyrazole, administered i.v. every 4 weeks in patients with advanced solid tumors: a phase I study group trial of the Central European Society of Anticancer-Drug Research (CESAR) Anti-Cancer Drugs ·K. Mross, M. E. Scheulen, Thomas Licht, Clemens Unger, Heike Richly, 五條しおり, Klaus Kutz, 宮下卓也, Paola Barbieri, Leticia Santos Avila Constâncio, Bruno Vincenzi, A. Bernareggi	2004	3
16	Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer International Journal of Clinical Pharmacology and Therapeutics ·Heike Richly, P. Kupsch, Cristiane Garcia Sanchez e Souza, M. Grubert, Xu PeiFang, R. Voigtmann, Brian Schwartz, E. Brendel, O. Christensen, Catherine G. Haase, Dirk Strumberg	2004	44
17	Results of a phase I trial of BAY 43–9006 in combination with doxorubicin in patients with refractory solid tumors Journal of Clinical Oncology ·Heike Richly, P. Kupsch, Μαρία Ιωάννης Μαρίνη, Der‐Zen Liu, Ralf A. Hilger, Catherine G. Haase, Brian Schwartz, M. E. Scheulen, S. Seeber, Dirk Strumberg	2004	17
18	A phase I clinical and pharmacokinetic study of the camptothecin glycoconjugate, BAY 38-3441, as a daily infusion in patients with advanced solid tumors Annals of Oncology ·K. Mross, Heike Richly, N. Schleucher, S. Korfee, Mitra Tewes, M. E. Scheulen, S. Seeber, T. Beinert, Michael Schweigert, Uwe Sauer, Clemens Unger, Dirk Behringer, E. Brendel, Catherine G. Haase, D. Voliotis, Dirk Strumberg	2004	21
19	A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors International Journal of Clinical Pharmacology and Therapeutics ·Heike Richly, P. Kupsch, Cristiane Garcia Sanchez e Souza, M. Grubert, Xu PeiFang, Мелехова Кристина Павловна, D. Voliotis, M. E. Scheulen, S. Seeber, Dirk Strumberg	2003	21
20	Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors International Journal of Clinical Pharmacology and Therapeutics ·Dirk Strumberg, D. Voliotis, J Moeller, Ralf A. Hilger, Heike Richly, Мелехова Кристина Павловна, Carl G. Beling, M. E. Scheulen, S. Seeber	2002	92

About Heike Richly

Heike Richly is a scholar working on Oncology, Ophthalmology, Cancer Research, Pulmonary and Respiratory Medicine and Hepatology, having authored 56 papers that have together received 2.4k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (20 papers), Ocular Oncology and Treatments (8 papers), Colorectal Cancer Treatments and Studies (8 papers), Melanoma and MAPK Pathways (7 papers), Advanced Breast Cancer Therapies (7 papers), Microtubule and mitosis dynamics (6 papers), HER2/EGFR in Cancer Research (6 papers) and Cancer Genomics and Diagnostics (6 papers). The work is most often cited by research in Hepatology (360 citations), Oncology (1.2k citations), Cancer Research (380 citations), Pulmonary and Respiratory Medicine (736 citations) and Pathology and Forensic Medicine (326 citations). Heike Richly has collaborated with scholars based in Germany, United States and Switzerland. Frequent co-authors include Dirk Strumberg, M. E. Scheulen, Brian Schwartz, Ralf A. Hilger, Ahmad Awada, E. Brendel, S. Seeber, R. Voigtmann, D. Voliotis and N. Schleucher. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer, Cancer Chemotherapy and Pharmacology and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact